High CRP Predicts Poor RCC-Specific Survival in Hemodialysis Patients
Study shows a 3.5x increased risk of death from renal cancer in HD patients undergoing nephrectomy.
Kenji Omae, MD, and colleagues at Tokyo Women's Medical University examined cancer-specific survival in a group of 315 patients with end-stage renal disease requiring hemodialysis and who had nephrectomy for RCC. Of these patients, 75 (23.8%) had elevated CRP levels prior to surgery, defined as a level above 0.5 mg/dL. The median follow-up was 51 months.
The 5-year cancer-specific survival rate was 69.9% for patients with elevated CRP compared with 95.2% for those with CRP levels of 0.5 mg/dL or less, the investigators reported online ahead of print in Urologic Oncology. In multivariate analysis, preoperative CRP levels independently predicted cancer-specific survival, with an elevated CRP level associated with a significant 3.5 times increased risk of death from cancer.
“We propose that routine measurement of this widely available and inexpensive biomarker could allow better risk stratification and risk-adjusted follow-up of these patients,” the investigators concluded.